Cortexyme Announces Presentation of Data Revealing Link Between Bacterial Pathogen and Genetic Risk for Alzheimer?s Disease

SAN DIEGO & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cortexyme, Inc. (Nasdaq: CRTX) today announced the presentation of new data supporting the on-target activity of COR388, its lead investigational medicine, and linking the ?gingipain hypothesis? for Alzheimer?s disease (AD) to the significance of the APOE gene as a major risk factor for the disease. Michael Detke, M.D., Ph.D., the company?s chief medical officer, detailed the results in an oral presentation (abstract #OC28) at the 2019 C